Open AccessOne-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume ® Drug-Coated Balloon for Anterior Urethral Strictures
Author(s) -
Sean P. Elliott,
Karl Coutinho,
Kaiser Robertson,
Richard D’Anna,
Kent Chevli,
Serge Carrier,
Mélanie Aubé-Peterkin,
Christopher H. Cantrill,
Michael Ehlert,
Alexis E. Te,
Jeffrey Dann,
Jessica DeLong,
Steven B. Brandes,
Judith C. Hagedorn,
Richard Levin,
Amy Schlaifer,
Euclid DeSouza,
David S. DiMarco,
Beth Erickson,
Richard Di Natale,
Douglas A. Husmann,
Allen F. Morey,
Carl A. Olsson,
Ramón Virasoro
Publication year - 2022
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000002346
Subject(s) - medicine , dysuria , randomized controlled trial , balloon dilation , cystoscopy , surgery , clinical endpoint , international prostate symptom score , urethra , balloon , urinary system , adverse effect , urology , lower urinary tract symptoms , prostate , cancer
The Optilume® drug-coated balloon (DCB) is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III study is a randomized, single-blind trial evaluating the safety and efficacy of the Optilume DCB against endoscopic management of recurrent anterior urethral strictures.